Cargando…
Durability of transgene expression after rAAV gene therapy
Recombinant adeno-associated virus (rAAV) gene therapy has the potential to transform the lives of patients with certain genetic disorders by increasing or restoring function to affected tissues. Following the initial establishment of transgene expression, it is unknown how long the therapeutic effe...
Autores principales: | Muhuri, Manish, Levy, Daniel I., Schulz, Martin, McCarty, Douglas, Gao, Guangping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077371/ https://www.ncbi.nlm.nih.gov/pubmed/35283274 http://dx.doi.org/10.1016/j.ymthe.2022.03.004 |
Ejemplares similares
-
Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?
por: Zhan, Wei, et al.
Publicado: (2021) -
rAAV-delivered PTEN therapeutics for prostate cancer
por: Ai, Jianzhong, et al.
Publicado: (2021) -
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
por: Shen, Weiran, et al.
Publicado: (2022) -
MicroRNA-regulated, Systemically Delivered rAAV9: A Step Closer to CNS-restricted Transgene Expression
por: Xie, Jun, et al.
Publicado: (2011) -
Production of rAAV by plasmid transfection induces antiviral and inflammatory responses in suspension HEK293 cells
por: Chung, Cheng-Han, et al.
Publicado: (2023)